TOPIRAMATE Extended Release Capsules: payments to doctors
Payments that named TOPIRAMATE Extended Release Capsules as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Upsher-smith Laboratories LLC?
Upsher-smith Laboratories LLC reported the most payments naming TOPIRAMATE Extended Release Capsules. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $26K
- Providers
- 700
- Transactions
- 1,472
- Average per transaction
- $18
The per-transaction average — $18 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 700 providers the average total is $37, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Upsher-smith Laboratories LLC | $26,052 | 100.0% |
Other products from Upsher-smith Laboratories LLC
The company that reported the most payments naming TOPIRAMATE Extended Release Capsules also reports against these.
- TOSYMRA$487,743
- ZEMBRACE SYMTOUCH$420,937
- Tosymra Sumatriptan Nasal Spray$251,851
- QUDEXY XR Topiramate Extended Release Capsules$234,466
- Zembrace SymTouch Sumatriptan Injection$220,738
- TORPENZ$20,976
- QUDEXY$20,782
- VIGADRONE$17,492
- VIGAFYDE$12,299
- VIGADRONE (vigabatrin) for Oral Solution$3,589